PRA is proud to join forces with a group of highly skilled and experienced patient advocates — collectively working towards improving the way patients with rare diseases are integrated into the clinical development lifecycle.
About the Committee
The Rare Diseases Advisory Committee (RDAC) is an independent and autonomous volunteer group that advises and works with PRA’s Center for Rare Diseases. Together they work to better understand the ways in which clinical trials can be revolutionized to be more effective and accessible for these patients and their unique challenges.
The inaugural committee members are a group comprised of experienced and talented individuals, all with a deep connection to the rare diseases community.
About the Collaboration
Working alongside the RDAC is the international team of experts at PRA’s Center for Rare Diseases. This team has dedicated itself to groundbreaking research and the development of life-changing therapies — specifically for patients with rare diseases. Since 2012, the Center has served more than 50,000 patients in over 300 clinical studies, leading to 18 approved drugs that fight rare diseases.
Ask the Experts: How are Digital Therapeutics Revolutionizing the Way We Approach Healthcare?
The buzz term in our industry right now is digital therapeutics. This term means using technology to supplement traditional clinical therapy methods.…
Lupus Awareness Month: Coping with an Autoimmune Disease During a Global Pandemic
Lupus is a chronic autoimmune disease that occurs when your body's immune system attacks your tissues and organs. Inflammation caused by lupus can…
International Nurses Day 2020: Former Nurses Share Experiences on the Frontlines
As part of our contribution to International Nurses Day, we spoke with a few of our 2,300 PRA employees with nursing backgrounds. They share what…